Sona Nanotech IncCanadian Securities Exchange:SONAView on OTCQB
- LAST PRICE0.2700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.2700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SONA |
|---|---|---|
| 11:50 ET | 2500 | 0.26 |
| 01:56 ET | 10000 | 0.255 |
| 02:14 ET | 500 | 0.27 |
Nov 7, 2024
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update, from 8:16AM ET on Thursday Nov 07, 2024 by Dow Jones
8:16AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sona Nanotech Inc | 30.2M | -8.7x | --- |
Thiogenesis Therapeutics Corp | 28.7M | -6.5x | --- |
Pharmala Biotech Holdings Inc | 26.9M | -38.5x | --- |
Biomind Labs Inc | 25.2M | -24.7x | --- |
Defence Therapeutics Inc | 24.5M | -2.0x | --- |
Resverlogix Corp | 16.7M | -1.0x | --- |
Company Information
Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.
Contact Information
- Headquarters
- Purdy's Wharf Tower 2 1969 Upper Water St Suite 2001HALIFAX, NS, Canada B3J 3R7
- Phone
- 902-442-0653
- Fax
- 902-482-1240
Executives
- President, Chief Scientific Officer
- Darren Rowles
- Chief Executive Officer
- David Regan
- Chief Financial Officer, Corporate Secretary
- Robert Randall
- Director
- Harold Megann
- Director
- Wayne Myles
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 111.7M |
Sona Nanotech Inc does not pay a dividend. | |
Beta | -1.66 |
EPS | $-0.03 |
Book Value | $0.01 |
P/E Ratio | -8.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
